<DOC>
	<DOCNO>NCT02603107</DOCNO>
	<brief_summary>This study evaluate safety efficacy switch fix dose combination ( FDC ) bictegravir/emtricitabine/tenofovir alafenamide ( B/F/TAF ) versus continue regimen consist boost atazanavir ( ATV ) darunavir ( DRV ) plus either emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF ) abacavir/lamivudine ( ABC/3TC ) HIV-1 infected adult virologically suppress .</brief_summary>
	<brief_title>Safety Efficacy Switching From Regimens Consisting Boosted Atazanavir Darunavir Plus Either Emtricitabine/Tenofovir Abacavir/Lamivudine Bictegravir/Emtricitabine/Tenofovir Alafenamide Virologically Suppressed HIV-1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Key Currently receive daily antiretroviral regimen consist ritonavir cobicistat boost ATV DRV plus either FTC/TDF ABC/3TC ≥ 6 month precede screen visit Adequate renal function : Estimated glomerular filtration rate ≥ 50 mL/min ( ≥ 0.83 mL/sec ) accord Cockcroft Gault formula Life expectancy ≥ 1 year Currently stable regimen ≥ 6 month precede screen visit document plasma HIV1 RNA &lt; 50 copies/mL ≥ 6 month precede screen visit ( undetectable HIV1 RNA level accord local assay use limit detection ≥ 50 copies/mL ) Have document suspect resistance FTC , tenofovir , ABC 3TC , include limited reverse transcriptase resistance mutation K65R M184V/I No previous use approve experimental integrase strand transfer inhibitor ( INSTI ) Key An opportunistic illness indicative stage 3 HIV diagnose within 30 day prior screen Individuals experience decompensated cirrhosis ( eg , ascites , encephalopathy , variceal bleeding ) Have treat immunosuppressant therapy chemotherapeutic agent within 3 month study screening , expect receive agent systemic steroid study ( eg , corticosteroid , immunoglobulin , immune cytokine base therapy ) Current alcohol substance use judge Investigator potentially interfere subject study compliance A history ongoing malignancy ( include untreated carcinoma insitu ) cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma . Individuals biopsyconfirmed cutaneous KS eligible , must receive systemic therapy KS within 30 day Day 1 anticipate require systemic therapy study Active , serious infection ( HIV 1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Day 1 Participation clinical trial , include observational study , without prior approval sponsor prohibit participate trial Any clinical condition prior therapy , opinion Investigator , would make individual unsuitable study unable comply dose requirement Any known allergy excipients B/F/TAF FDC ATV , RTV , DRV , COBI , FTC/TDF ABC/3TC Females pregnant ( confirm positive serum pregnancy test ) Females breastfeed Acute hepatitis 30 day prior study entry Chronic hepatitis B infection individual TDF contain regimen , determine either : Positive hepatitis B virus ( HBV ) surface antigen negative HBV surface antibody , regardless HBV core antibody status , screen visit Positive HBV core antibody negative HBV surface antibody , regardless HBV surface antigen status , screen visit Active tuberculosis infection Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>